Beyond cardiovascular outcomes, SGLT2 inhibitors markedly slow CKD progression, reducing renal-endpoint risk by ≈30–40% irrespective of baseline kidney function [38]. The gene discussed is SLC5A2; the disease is chronic kidney disease.